Skip to main content

GSK plc 6-K, filed Nov 18, 2026

GSK plc (GSK)

6-K 2026-11-18 For: 2026-11-18
View Original
Added on November 18, 2026

About this 6-K

GSK plc filed this 6-K on November 18, 2026.

GSK said the FDA granted accelerated approval to Nelkarmi (neladalkib) for previously treated advanced ALK-positive non-small cell lung cancer. In the trial, the confirmed overall response rate was 49% (33/67) in patients previously treated with alectinib only. AI summary